Skip to main content
Oncopeptides logo

Oncopeptides — Investor Relations & Filings

Ticker · ONCO ISIN · SE0009414576 LEI · 549300J9WWQ5CBYQ1M77 ST Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2019-12-09 Regulatory Filings
Country SE Sweden
Listing ST ONCO

About Oncopeptides

https://www.oncopeptides.com/en

Oncopeptides is a biotechnology company focused on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company concentrates on hematological diseases, with a primary focus on multiple myeloma. Its commercialized product is Pepaxti (melflufen), a peptide-drug conjugate for adult patients with relapsed or refractory multiple myeloma. Founded in 2000 based on research from leading cancer institutions, Oncopeptides leverages its proprietary technology platforms to advance a pipeline of innovative drug candidates. The company's research also includes the development of Natural Killer (NK) cell engagers to address unmet medical needs in oncology.

Recent filings

Filing Released Lang Actions
Oncopeptides presenterar lovande data från fas 2-kombinationsstudien ANCHOR i patienter med RRMM vid ASH:s årsmöte 2019
Regulatory Filings Classification · 1% confidence The document is a press release dated December 8, 2019, announcing the presentation of updated clinical trial data (ANCHOR study results) from the company Oncopeptides at the American Society of Hematology (ASH) annual meeting. It details scientific findings, quotes management, and provides links to where the presentation materials can be found on the company website. This format—a news announcement summarizing scientific/clinical progress rather than the full financial report (10-K/IR) or a formal presentation deck (IP)—is characteristic of an Earnings Release (ER) or a general announcement. Since it focuses on clinical data presentation at a major conference rather than quarterly financial performance highlights, and it is not a formal presentation deck (IP) or a transcript (CT), it fits best as an Earnings Release (ER) if the context implies this is the primary way they communicate period results, or potentially a Regulatory Filing (RNS) if it's purely scientific disclosure. However, given the structure (headline, key data points, management commentary, and announcement of where the presentation is available), it strongly resembles an Earnings Release (ER) announcing key operational/clinical milestones, even if the primary focus is scientific data presented at a third-party meeting. It is not a formal financial report (10-K/IR) or a presentation file (IP). Given the context of clinical data release, ER is the most appropriate fit among the options for a significant operational update.
2019-12-09 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report Classification · 1% confidence The document is a 'Delårsrapport Q3 2019' (Interim Report for Q3 2019) for Oncopeptides AB. It contains comprehensive financial data, including income statements, cash flow, and balance sheet summaries for the period of July to September 2019, as well as detailed management commentary on clinical trials and operational progress. It is not an announcement of a report, but the report itself, containing substantive financial data. Q3 2019
2019-11-19 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report Classification · 1% confidence The document is titled 'INTERIM REPORT Q3 2019' and contains comprehensive financial data, including a summary of Q3, financial overview tables for the group, and detailed management commentary on clinical trials and operational development. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. 9M 2019
2019-11-19 English
Extra bolagsstämma i Oncopeptides AB (publ)
AGM Information Classification · 1% confidence The document is explicitly titled "EXTRAORDINARY GENERAL MEETING IN ONCOPEPTIDES AB (PUBL)" and provides the date, location, and detailed procedures for shareholder participation, including voting rights registration and proxy instructions. The agenda items clearly relate to resolutions to be voted upon at this meeting (e.g., 'Resolution on issue of warrants under Co-worker LTIP 2019'). This content directly corresponds to materials presented or discussed at a General Meeting, fitting the definition of AGM Information (AGM-R), even though it is an Extraordinary General Meeting (EGM) notice, which falls under the broader category of meeting materials.
2019-11-14 English
Extraordinary General Meeting in Oncopeptides AB (publ)
AGM Information Classification · 1% confidence The document is explicitly titled "EXTRAORDINARY GENERAL MEETING IN ONCOPEPTIDES AB (PUBL)" and details the notice, agenda, and proposed resolutions for this meeting, including items related to warrant issues (Co-worker LTIP 2019 and Board LTIP 2019) and authorization for future share issues. This content directly corresponds to the purpose of an Annual General Meeting (AGM) or Extraordinary General Meeting (EGM) notice/materials. Therefore, the appropriate classification is AGM-R (AGM Information). The document length is substantial (over 19k characters), confirming it is the primary material, not just an announcement of a report.
2019-11-14 English
Major Shareholding Notification 2019
Major Shareholding Notification Classification · 1% confidence The document details a change in shareholding for Handelsbanken Fonder AB in Oncopeptides AB. It explicitly states the 'Reason for major shareholding notification Buy' and provides detailed tables showing the 'Before the transaction' and 'After the transaction' share quantities and resulting percentages (5.05%). This content directly corresponds to the definition of a Major Shareholding Notification, which tracks when ownership crosses specific thresholds. The appropriate code is MRQ.
2019-11-08 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.